Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
about
Proteomic-Based Approaches for the Study of Cytokines in Lung CancerOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsCADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity.Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerInflammation and skeletal metastasisStochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapyDiscovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesisMyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.Therapy-induced tumour secretomes promote resistance and tumour progressionJAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.High throughput and automatic colony formation assay based on impedance measurement technique.Identification of novel small molecules that inhibit STAT3-dependent transcription and function.AKT Inhibition Promotes Nonautonomous Cancer Cell SurvivalOverexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide.Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival RatesInsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.A combinatorial strategy for treating KRAS-mutant lung cancerEpithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis.MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer.Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation
P2860
Q26738539-AD50F8EE-8969-4272-8486-0B8E4F8C0060Q26774625-79CF8AE5-99FF-40BC-B543-D2D4F775FF34Q27323547-F520D8B2-FC9C-47E7-B875-8C2D971A0F12Q28076462-9DD81E9F-7479-4E09-936A-5BFFB7AAA814Q28079309-7F0A4FB2-0AB8-477E-B3D9-A6F89DEC414AQ28259999-8784D2D0-DEAB-4D77-8CF3-844C98D7D18DQ28396089-944CAB89-0AA9-45C4-9B3C-823C98B42438Q28830465-8A7F75A8-2E31-4039-8C05-65CC740B9A8BQ33551693-64B99C7F-9D7A-4DF4-BF6A-95E4BF5CAF4AQ33566948-1864D70A-8038-451A-ABA4-7AA59954F15AQ33614314-FC678A4A-2148-4962-AC10-D129F45D0332Q33902576-C56429CC-6EDB-4C48-B148-645008805958Q34525925-3B2C93B4-BF34-4B2C-9E4E-718196D1C864Q35196919-21510510-BE77-4BE9-BF75-8C77FDA9977BQ35463538-17447138-138F-4F4C-86A6-A9324EB8C62AQ35867131-B56600DB-EFCB-4662-98E6-4BBEDA09F920Q35987345-0DC33F57-BF96-45F8-A93F-8D03547C1992Q35987390-0BD423E8-80AC-4303-BCEB-66D81140B847Q36145016-9A309D05-7294-4E91-9EA5-95096D80C782Q36299021-A2A8EBAE-4BBA-4C4F-8501-6B8D1C7E0E3DQ36411459-CEF7B16A-F166-431D-A10E-C70C35858776Q36447471-6D564F9D-5B1E-4E6A-99EC-A35E73D38542Q36544047-262BB909-D8C4-4F77-875B-6A1E2574A01AQ36554387-B5149DF3-8B38-4630-8BB9-46E02725595DQ36561640-5B559DB0-9532-4AC8-BF72-4DABA6A611CEQ36571455-BC3A9F18-671D-49E3-8E78-1A4C918CF4C7Q36599823-2959ACDD-B1AE-4C60-BA72-4AE42B293662Q36629433-78B823AA-2B45-4E04-A518-F6826FA0AAB0Q36634818-D572DE76-83A3-4994-B71C-C899D8BC11F5Q36759183-D4F534E9-7B26-421A-87D6-08B870103B64Q36782872-A686D95B-D76C-4294-8D5D-642C8B71040EQ36970403-4E6F0B31-9E3C-41CA-A85E-BF6A47AD4123Q36989342-4BD9FE50-C157-4A42-B7A8-00E8FF689A9EQ36998301-5A965FCF-84EA-48D8-AE4D-8D6550EAC65FQ37080881-01B861E5-6E13-4017-9A20-DE4793D41793Q37119697-6A187C6C-00CA-4BF2-8A05-26DCC11D8699Q37156891-472A3C07-894B-486A-BED4-B92A0EEAB096Q37190200-980BFD0A-ED44-421F-9C51-40476F4A01CFQ37269340-96AD1F95-7B11-454C-9177-53263189E69CQ37376285-E240B8B0-401A-45A0-8292-B836615D8188
P2860
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
@en
type
label
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
@en
prefLabel
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
@en
P2093
P1433
P1476
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
@en
P2093
P304
P356
10.1016/J.CCR.2014.05.019
P577
2014-07-24T00:00:00Z